Zhu W, Han M, Wang Y, Wang G. Trend Analysis and Prediction of the Incidence and Mortality of CKD in China and the US. BMC Nephrol. 2024; 25:76.
Hustrini NM, Susalit E, Lydia A, Marbun MBH, Syafiq M, Yassir, et al. The etiology of kidney failure in Indonesia: A multicenter study in tertiary care centers in Jakarta. Ann Glob Health. 2023; 89:36.
Indonesian Society of Nephrology. 11th Annual Report of the Indonesian Renal Registry, 2018. Bandung: Indonesian Society of Nephrology; 2018.
Indonesian Ministry of Health. Indonesian Health Profile. 2021. Jakarta: Indonesian Ministry of Health; 2021.
Kim HY, Yoo TH, Hwang Y, Lee SW, Lee JH, Kang SW, et al. Indoxyl Sulfate (IS)-Mediated Immune Dysfunction Provokes Endothelial Damage in Patients with End-Stage Renal Disease (ESRD). Sci Rep. 2017; 7:3057.
Takkavatakarn K, Phannajit J, Udomkarnjananun S, Chariyavilaskul P, Sitticharoenchai P, Tangchitthavorngul S. Association between Indoxyl Sulfate and Dialysis Initiation and Cardiac Outcomes in Chronic Kidney Disease Patients. Int J Nephrol Renovasc Dis. 2022; 15:115–26.
Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al. Association between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results from the KNOW-CKD. J Am Heart Assoc. 2019;8: e011162.
Lavoie L, Hanane K, Sharon W, Le Grand B, Kosmynin A, Larouche J. Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review. Cardiovasc Ther. 2016:152–60.
Poudel I, Tejpal C, Rashid H, Jahan N, Qazi SA, Ahsan A, et al. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-Elevation Myocardial Infarction? A Literature Review. Cureus. 2019;11: e5280.
Kirthi AA, Yasmin A, Artha M, Nugraha D, Santosa A. Hipertensi Sebagai Prediktor Kejadian Kardiovaskular Mayor pada Pasien Infark Miokard Akut pada Tahun 2018 di RSUP Sanglah Denpasar, Bali-Indonesia. Intisari Sains Medis. 2019; 10:530–6.
Qanitha A, Uiterwaal CSPM, Henriques JPS, Alkatiri AA, Atsma DE, de Mol BAJM. Characteristics and the Average 30-Day and 6-Month Clinical Outcomes of patients hospitalized with coronary artery disease in a poor South-East Asian setting: The first cohort from Makassar Cardiac Center, Indonesia. BMJ Open. 2018;8: e021996.
Tsai IT, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, et al. Burden of major adverse cardiac events in patients with Coronary Artery Disease. BMC Cardiovasc Disord. 2017; 17:1.
Fan PC, Chang JCH, Lin CN, Lee CC, Chen YT, Chu PH, et al. Serum Indoxyl Sulfate Predicts Adverse Cardiovascular Events in Patients with Chronic Kidney Disease. J Formos Med Assoc. 2019; 118:1099–106.
Iwasaki K, Miyoshi T, Urabe C, Sakuragi S, Kawai Y, Fuke S, et al. Impact of serum indoxyl Sulfate on One-Year Adverse Events in chronic kidney disease patients with heart failure. J Clin Med. 2024; 13:4413.
Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clin J Am Soc Nephrol. 2009; 4:1551–8.
Takkavatakarn K, Phannajit J, Udomkarnjananun S, Tangchitthavorngul S, Chariyavilaskul P, Sitticharoenchai P, et al. Association between indoxyl sulfate and dialysis initiation and cardiac outcomes in patients with chronic kidney disease Int J Nephrol Renovasc Dis. 2022;15:115–26.
Li Q, Zhang S, Wu QJ, Xiao J, Wang ZH, Mu XW, et al. Serum Total Indoxyl Sulfate Levels and All-Cause and Cardiovascular Mortality in Maintenance Hemodialysis Patients: A Prospective Cohort Study. BMC Nephrol. 2022; 23:231.
Cao XS, Chen J, Zou JZ, Zhong YH, Teng J, Ji J, et al. Association of Indoxyl Sulfate with Heart Failure among patients undergoing hemodialysis. Clin J Am Soc Nephrol. 2015; 10:111–9.
Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced Chronic Kidney Disease. Arch Med Res. 2012; 43:451–6.
Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major Adverse Cardiovascular Event Definitions Used in Observational Analysis of Administrative Databases: A Systematic Review. BMC Med Res Methodol. 2021; 21:241.
Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. J Am Heart Assoc. 2017;6: e005022.
Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uroemic toxin, directly affect cardiac fibroblasts and myocytes? Eur Heart J. 2010; 31:1771–9.
Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, et al. Oral Charcoal Adsorbent (AST-120) prevents the progression of cardiac damage in chronic kidney disease by suppressing oxidative stress. Nephrol dial transplants. 2009; 24:2089–95.
Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialyzable uremic toxin, indoxyl sulfate. PLoS One. 2012;7: e41281.
Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, et al. Indoxyl sulfate stimulates proliferation of Rat Vascular Smooth Muscle Cells. Kidney Int. 2006; 69:1780–5.
Shimizu H, Hirose Y, Nishijima F, Tsubakihara Y, Miyazaki H. ROS and PDGF-β receptors are critically involved in indoxyl sulfate action that promotes vascular smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol. 2009;297:C389–97.
Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl Sulphate and Indoxyl Sulphate Predict Progression of Chronic Kidney Disease. Nephrol dial transplants. 2011; 26:938–47.